Cinemo ICO™ Agent Store Brings Agentic AI to the Heart of the Intelligent Cockpit
Cinemo, a globally recognized one-stop-shop provider of fully integrated digital media products, announced Cinemo ICO™ Agent Store, an embedded and cloud-native agentic platform. It delivers unparalleled agentic AI-powered experiences across vehicles from Cinemo and third parties.
Cinemo ICO™ Agent Store is a powerful enhancement to any AI application such as AI Assistants – both locally in the car and in the cloud. It provides a growing range of specialized and highly optimized agents and tools powered by a range of third-party services, enabling rich and automotive-grade user experiences. For example, email and calendar productivity, trip planning, reservations, food ordering, home control, and many more agents and tools can all be fully managed by the OEMs in real-time.
Cinemo ICO™ Agent Store delivers a unified Agent-as-a-Platform approach, enabling OEMs and partners to configure, manage, and deploy intelligent agents, tools, apps, and services across vehicles and fleets - instantly and securely. The agent store acts as a one-stop shop for third-party Agentic AI offerings, removing the complexity of individual negotiations, contracting, and bespoke technical integrations for the OEMs.
“Agentic AI is progressing at a speed never seen before, and with the new Cinemo ICO™ Agent Store this progress can be instantaneously made available in the car,” says Richard Lesser, CEO of Cinemo. “OEMs strive to deliver the best possible user experience. The Cinemo ICO™ Agent Store empowers them to freely select the best agentic AI at any time—without compromise and without requiring app downloads.”
About Cinemo
Cinemo is a global provider of innovative infotainment products designed to create seamless digital media experiences. Its portfolio features award-winning, fully integrated, system-agnostic solutions that combine low footprint with high performance and quality.
Founded in 2008, Cinemo provides world-leading digital media solutions for the highly demanding automotive market. Trusted by more than 40 market-leading OEMs and over 20 tier-1 suppliers, Cinemo has a strong track record of industry firsts.
By leveraging its field-proven digital media, cloud, and AI technologies, Cinemo has expanded its range to create the first open cloud ecosystem that connects devices, content, and users.
Cinemo’s global team of innovative thinkers, representing over 40 nationalities, is dedicated to driving continuous growth and developing digital media solutions that create value for our customers and partners.
Further information is available at www.cinemo.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260108987958/en/
Contacts
Press contacts
Cinemo | Martina Oerther, Marketing Director (moerther@cinemo.com)
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press Release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press Release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press Release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press Release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press Release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom